Treatment Trials
Below is a listing by cancer type of the current treatment clinical trials for cancer offered through the Genesis Cancer Care Institute and Iowa Cancer Specialists. See clinical trials offered by Hematology-Oncology Associates of the Quad-Cities, PC.
Each trial below is linked to a complete description provided by the National Cancer Institute. You may then choose a patient version or health professional version to read and print out as you wish. If you need assistance with this process, contact us. You may search for other clinical trials through the following links: National Cancer Institute Clinical Trial Search; Emerging Med; Trial Check; or Center Watch.
Breast Cancer
NSABP B-39: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) vs Partial Breast Irradiation (PBI) for Women With Stage 0, I or II Breast Cancer (Partial Closure)
NSABP B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
NSABP B-46 (Industry): A Phase III Clinical Trial Comparing the Combination of TC Alone and to TAC for Women with Node Positive or High-Risk Node Negative, HER2-Negative Breast Cancer
NSABP B-47 : A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel + Cyclophosphamide or Four Cycles of Doxorubicin + Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy + Trastuzumab in Women With Node-Positive or High Risk Node-Negative HER2-Low Invasive Breast Cancer
SWOG S0221: Phase III Trial of Continuous Schedule AC + G vs Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer
CALGB 40502: A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-Paclitaxel or Ixabepilone Combined With or Without Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer (Partial Closure - Ixabepilone Arm)
NCCTG N0733: Phase II Trial of Capecitabine and Lapatinib With or Without IMC-A12 in Patients With HER2 (+) Breast Cancer Previously Treated With Trastuzumab and an Anthracycline and/or a Taxane
back to top
Carcinoid Tumor
SWOG S0518: Phase III Prospective Randomized Comparison of Depot Octreotide + Interferon Alpha vs Depot Octreotide + Bevacizumab in Advanced, Poor Prognosis Carcinoid Patients
back to top
Gastro-Intestinal (Colon Cancer; Rectal Cancer; Gastrointestional Stromal Tumor)
CALGB/SWOG 80702: Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer
CALGB 80405: A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin With Bevacizumab or Cetuximab for Patients With Untreated Metastatic Adenocarcinoma of the Colon or Rectum
back to top
Genito-Urinary (Prostate; Kidney)
CALGB 90203 : Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy vs Immediate Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer
back to top
GYNECOLOGY (Endometrial; Ovarian Epithelial)
back to top
Head & Neck
back to top
Leukemia (Acute Myeloid (AML) Adult; Chronic Lymphocytic (CLL))
SWOG S9910: Leukemia Centralized Reference Lab and Tissue Repositories-Consent to Perform Cellular and Molecular Studies in Leukemia Patients
back to top
Lung (Non-Small Cell)
SWOG S0720: Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
SWOG S0802 : Randomized Phase II Trial of Weekly Topotecan With and Without AVE0005 in Patients With Platinum Treated Extensive Stage Small Cell Lung Cancer (E-SCLC) (Partial Closure - Platinum Refractory Stratum)
ECOG 1505: Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm)-IIIA Non-Small Cell Lung Cancer (NSCLC)
ECOG 5508 : Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
CALGB 30801 : A Randomized Phase III Double-Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer (NSCLC)
back to top
Lymphoma
back to top
Melanoma
SWOG S0933 : Phase II Study of RO4929097 in Advanced Melanoma
back to top
Miscellaneous
SWOG S0702: Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
CALGB 70604: Randomized, Phase III Study of Standard Dosing vs Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
back to top
Multiple Myeloma
SWOG S0309: Myeloma Specimen Repository Protocol, Ancillary
ECOG 1A06: An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide vs Melphalan, Prednisone and Lenalidomide in Newly Diagnosed Myeloma Patients Who Are Not Candidates for High-Dose Therapy
ECOG 3A06 : Randomized Phase III Trial of Lenalidomide vs Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
back to top
